We are exploring the use of interferon (IFN) genes for somatic cell gene therapy and have investigated the possibility of transforming cells into low constitutive IFN producers over prolonged periods of time without impeding cell survival or replication. Here we report the possibility of conferring a permanent antiviral state to cells by introducing an IFN-, gene with a modified transcriptional control. This was achieved by placing the murine IFN-jl-coding sequence behind the IFN-inducible 0.6-kb XhoII-NruI promoter region of the H-2K" major histocompatibility complex gene. BALB/c 3T3 cells that are normally permissive for virus infection were transformed with this construction, and 14 of the 21 clonal cell lines obtained displayed different levels of enhanced resistance to the replication of vesicular stomatitis virus, encephalomyocarditis virus, and Semliki Forest virus. The permanent antiviral state was dependent on the presence of new IFN-l fragments in Southern blots and was accompanied by very low constitutive synthesis of IFN-I, and the presence of construct-derived IFN mRNA could be demonstrated only after polymerase chain reaction amplification of cDNA. The antiviral state was stable over a 9-month period in culture, corresponding to about 250 cell generations, and did not affect cell replication, since the average population doubling time of these cells was not significantly different from that of the control clone. Twenty-nine control clonal cell lines, stably transformed with either the neo gene alone (22 lines) or the neo gene together with a mutated murine IFN-, gene coding for an inactive protein (7 lines), did not develop stable antiviral expression. We conclude that low constitutive synthesis of autocrine IFN-0 is sufficient to induce a permanent antiviral state, is compatible with cell survival and replication, and therefore merits further exploration for use in somatic cell gene therapy.
IFN-0 is sufficient to induce a permanent antiviral state, is compatible with cell survival and replication, and therefore merits further exploration for use in somatic cell gene therapy.
Current methods for the therapy of viral infections rely either on chemical compounds with antiviral action or on interferons (IFNs) (17) . This approach has met with some success in several instances, but there is still a long way to go before a satisfactory treatment for every virus disease becomes available. Genetic engineering offers novel ways of rendering cell resistant to virus infection. For example, Friedman et al. (16) have obtained mouse L cells resistant to herpes simplex virus type 1 infection by transforming them with a gene that constitutively expresses a mutated form of the VP16 protein, which inhibits the transcriptional activation of the virus by interfering with the transactivating function of native VP16. Chebath et al. (9) transformed hamster cells with an oligo(A) synthetase coding sequence under the control of the simian virus 40 early promoter and obtained cells that were constitutively resistant to encephalomyocarditis virus (EMCV) but not to vesicular stomatitis virus (VSV).
Baltimore has referred to this strategy to viral resistance as intracellular immunization and has suggested that it provides a novel approach to the treatment of viral infections, including infection with human immunodeficiency virus (HIV) (5) . In brief, this could represent a form of somatic cell gene therapy in which a dominant gene coding for a product with antiviral activity is used to transform a population of stem cells that then could give rise to virusresistant progeny. We have been exploring the possibility of using IFN genes for this purpose. IFNs have the advantage * Corresponding author.
of displaying a broad-spectrum antiviral activity which includes activity against retroviruses (12) . The long-term goal of our experiments is to explore the various possibilities offered by the IFN system, i.e., the genes coding for the different IFNs and for IFN-induced antiviral proteins, to find ways of establishing stable antiviral expression (SAVE) in hemopoietic stem cell-dependent populations, such as lymphocytes and macrophages. This is the necessary first step in exploring the possibility of using somatic cell gene therapy as a means of combating life-threatening viral infections with long incubation periods, for which no other therapeutic measures are available.
IFN genes or coding sequences have previously been used by others to transform cells, but this has usually been done in heterologous systems in which an IFN gene of one animal species was introduced into cells of a different species, such as the human (Hu) or mouse (Mu) IFN gene into Chinese hamster cells (26, 33 for 60 min and was terminated by heating to 98°C for 10 min. When necessary, the cDNA products were purified on Centricon-100 cartridges (Amicon Corp., Amherst, Mass.). Different conditions were used with the GGGGGGGG GGGGGGGTCCTT primer. In this case, the RNA and the primer were heated for 3 min in boiling water and immediately cooled to 45°C for 5 min.
One-tenth of the amount of cDNA obtained was amplified in a 100-,uJ PCR reaction mixture, using Thermus aquaticus DNA polymerase (T. aquaticus polymerase and buffer purchased from Perkin-Elmer Cetus) and a DNA thermal cycler (Perkin-Elmer Cetus). Each primer was present at a concentration of 0.2 ,uM, and the reaction was carried out in the presence of 2 mM MgCl2. The first denaturation took place at 98°C for 10 min, and each of the 30 following cycles was composed of three steps: 1 min at 94°C, 2 min at 55°C, and 2 min at 72°C.
The resistance to the three viruses, whereas none of the control clones gave virus titers significantly lower than the optimum titers (Tables 1 and 2 ). Although rankings of the clones were not exactly identical for the three viruses, clones that were clearly resistant to one virus also displayed a significant resistance to the two others. The fact that the correlation between the extent of the antiviral effect directed against the three different viruses was not always close is most likely a reflection of the different degrees of expression of the various antiviral pathways induced by IFN-P in each clone.
It has been shown, for example, that the same pathways are not responsible for the IFN-induced inhibition of EMCV and VSV (9) , and it is conceivable that we are observing clonal variation in the activation of these pathways. Detailed studies of these pathways in the clones should provide an answer to this question. anti-Mu IFN-P serum was able to partially abolish the antiviral state (C). To obtain this effect, pKb-neo-IFNp cells had to be cultured for 4 days in the presence of a 1:50 dilution of goat antiserum, being capable of neutralizing 4 U of IFN when diluted 100,000-fold (11) . The same concentration of antiserum had to be present in the agar overlay during the plaque assay. Although the monolayer was infected with a 10-2 dilution of the SFV stock, the number of plaques appearing was less than that obtained with a lo-3 dilution in the untreated control cells (A).
Antiviral resistance was dependent in all cases on the presence of new IFN-P fragments in Southern blots (Table   2 16, and 20). The antiserum had to be present during several rounds of cell replication before viral infection, and even then the sensitivity to viruses did not completely revert to that of the control clones, as illustrated for SFV in Fig. 3 .
This finding highlights the difficulty of neutralizing the effects of an autocrine IFN production, as opposed to the usual neutralization assay in which IFN and antiserum are incubated together before being added to cells. A similar phenomenon has been observed with other cytokines such as granulocyte-macrophage colony-stimulating factor (23) and interleukin-3 (8) .
Production of IFN-,l. The IFN present in the supernatants of pKb-neo-IFN,B and 3T3-E cells grown in the presence of 10% newborn calf serum was measured by a microtest assay using VSV as the challenge virus. The IFN output of control clones, and of pKb-neo-IFNp clones of moderate resistance, was below the detection level (less than 3 U/0.15 ml), whereas the production of pKb-neo-IFNp clone 13 (pKbneo-IFN,-13) amounted to 6 U/0.15 ml and up to 12 U/0.15 ml if the supernatant was dialyzed against Tris (pH 7.5) (this dialysis effect was a phenomenon never observed before on other cell types). The constitutive IFN production was also measured after concentration by poly(U) chromatography (13), using 4-day-old medium of cell monolayers refed without serum. We calculated that over a 4-day period, untransformed 3T3-E cells and pKb-neo cells had a level of IFN accumulation in the medium of about 200 molecules per cell. The IFN production of pKb-neo-IFN,B-13, which was one of the more resistant clones, was 10-fold above this basal level for at least 250 cell generations, whereas the IFN production of pKb-neo-IFNp-4 was intermediate ( construct-derived IFN-P RNA transcripts in the resistant clones (Fig. 4) The H-2Kb promoter is normally active in virtually all somatic cells, since the expression of major histocompatibility complex class I antigens is ubiquitous in the organism (15) . Among the regulatory factors that have been shown to bind to this promoter are three IFN response sequencebinding factors (IRS-BFs) (7, 20, 31) and the activators AP-1, KBF1, H2TF1, and NF-KB (4, 21, 35) . Exogenous IFN can augment transcription from the H-2Kb promoter by inducing an activating IRS-BF. A role for spontaneous endogenous IFN in control of the basal level of expression has not been demonstrated. It has been shown that an H-2Kb gene with a mutated IRS, irresponsive to IFN--y, can still be expressed (7) , but one can argue that the mutations may also prevent the binding of the silencing IRS-BFs.
What is the evidence that in the resistant clones IFN-,B synthesis is driven by the H-2Kb promoter? The analysis of reverse-transcribed RNA derived from representative resistant clones showed the presence of construct-derived IFN-P RNA transcripts, thus indicating that the H-2Kb promoter was active in directing IFN synthesis in the transformed cells. We also found that the IFN-P production of resistant clone pKb-neo-IFNI3-13 could be enhanced by exogenous IFN-a or -3, showing that the introduced IFN-4 gene is under the control of an IFN-inducible promoter.
Of 21 pKb-neo-IFNp clones, 5 (clones 1, 5, 9, 11, and 14 in 
